Data updated: Mar 10, 2026
OXALIPLATIN
OXALIPLATIN
Approved 2009-08-07
25
Indications
--
Phase 3 Trials
16
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2009-08-07
- Routes
- INTRAVENOUS, INJECTION
- Dosage Forms
- INJECTABLE
Companies
Pfizer Sun Pharma Teva EUGIA PHARMA GLAND NOVAST LABS MEITHEAL Fresenius Kabi Novartis MUSTAFA NEVSAT IIAC SANAYII A.S. PLIVA LACHEMA PHARMOBEDIENT Viatris CHARTWELL MOLECULAR SHANDONG QILU PHARM HAINAN AM REGENT HENGRUI PHARMA ACCORD HLTHCARE HETERO LABS LTD VI
Active Ingredient: OXALIPLATIN
Website: ↗
OXALIPLATIN Approval History
Loading approval history...
What OXALIPLATIN Treats
25 FDA approvalsOriginally approved for its first indication in 2009 . Covers 25 distinct patient populations.
- Other (25)
Other
(25 approvals)- • Approved indication (Aug 2009)
- • Approved indication (Sep 2009)
- • Approved indication (Jun 2010)
- • Approved indication (Jun 2010)
- • Approved indication (Jan 2011)
- • Approved indication (Apr 2011)
- • Approved indication (Aug 2012)
- • Approved indication (Aug 2012)
- • Approved indication (Apr 2014)
- • Approved indication (Jun 2014)
- • Approved indication (May 2016)
- • Approved indication (Jun 2016)
- • Approved indication (Jan 2017)
- • Approved indication (Feb 2017)
- • Approved indication (Mar 2017)
- • Approved indication (May 2017)
- • Approved indication (May 2017)
- • Approved indication (Sep 2017)
- • Approved indication (Nov 2017)
- • Approved indication (Mar 2018)
- • Approved indication (Oct 2018)
- • Approved indication (Feb 2019)
- • Approved indication (Jan 2024)
- • Approved indication (Jan 2025)
- • Approved indication (Jan 2026) New
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
OXALIPLATIN FDA Label Details
ProWant competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.